2 The histopathology of chronic myeloproliferative diseases

https://doi.org/10.1016/S0950-3536(98)80036-XGet rights and content

This chapter discusses the histopathology of five groups of chronic myeloproliferative diseases: chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, chronic idiopathic myelofibrosis and unclassifiable myeloproliferation. Histological staging of the four haematologically defined diseases is performed by grading the three most prominent variables: megakaryocytes, fibres and blasts. Histological outcome is correlated to the staging of diagnostic bone marrow biopsies; megakaryocytic involvement is correlated with the risk of myelofibrosis. An excess of blasts is related to the risk of leukaemic transformation. The progression of myelofibrosis depends on the grade of fibre increase at diagnosis. These three statements are highly significant and valid for all types of chronic myeloproliferative disorders. The results of cytogenetics are discussed in relation to the histological classification for these patient groups. Changes in bone marrow histology following myelosuppressive therapy is presented. Prospective studies under standardized protocol therapy are recommended, so that the long-term effects of therapy can be assessed.

References (99)

  • HehlmannR et al.

    Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia

    Blood

    (1994)
  • IshibashiT et al.

    Separation of human megakaryocytes by state of differentiation on continuous gradients of Percoll: Size and ploidy analysis of cells identified by monoclonal antibody to glycoprotein IIb/IIIa

    Blood

    (1986)
  • KreipeH et al.

    Clonal granulocytes and bone marrow cells in the cellular phase of Agnogenic myeloid metaplasia

    Blood

    (1991)
  • KurzrockR et al.

    Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course

    Blood

    (1990)
  • LandolfiR et al.

    Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo

    Blood

    (1992)
  • MarascaR et al.

    Might essential thrombocythemia carry Ph anomaly? Letter to Editor

    Blood

    (1998)
  • MartiatP et al.

    Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia

    Blood

    (1991)
  • NafeR et al.

    Quantitative cytomorphology of megakaryocytes in chronic myeloproliferative disorders—Analysis of planimetric and numeric characteristics by means of a knowledge based system

    Experimental Pathology

    (1990)
  • WadenvikH et al.

    The effect of α-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia

    Blood

    (1991)
  • WhiteNJ et al.

    Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B-cells

    Blood

    (1994)
  • BartlR et al.

    Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD)

    European Journal of Haematology

    (1993)
  • Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon α 2b for chronic myeloid leukemia

    Blood

    (1998)
  • BennettJM et al.

    The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical myeloid, and chronic myelomonocytic leukaemia

    British Journal of Haematology

    (1994)
  • BernhardsJ et al.

    A new histological embedding method by low-temperature polymerisation of methyl methacrylate allowing immuno- and enzyme histochemical studies on semi-thin sections of undecalcified bone marrow biopsies

    Histochemistry

    (1992)
  • BrandCM et al.

    Successful retreatment of an anti-interferon resistant polycythemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies

    British Journal of Haematology

    (1994)
  • BrunningRD et al.

    Atlas of Tumor Pathology: Tumors of the Bone Marrow

    (1994)
  • BuescheG et al.

    Numerical increase of pseudo-Gaucher cells in CML-indication of a more advanced stage of disease

    Blood

    (1995)
  • BuescheG et al.

    Square sampling. An easy method of estimating numerical density of cells or particles within a tissue

    Analytical and Quantitative Cytology and Histology

    (1997)
  • BuescheG et al.

    Frequency of pseudo-Gaucher cells within diagnostic bone marrow biopsies from patients with a Ph-positive CML

    Virchows Archive A

    (1997)
  • BuhrT et al.

    The impact of megakaryocyte proliferation for the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia

    Virchows Archive A

    (1992)
  • BuhrTh et al.

    Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts

    Annals of Hematology

    (1992)
  • CervantesF et al.

    Prognostic evaluation of initial bone marrow histopathological features in chronic granulocytic leukemia

    Acta Haematologica

    (1989)
  • ChottA et al.

    Interferon-alpha induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis

    British Journal of Haematology

    (1990)
  • CortelazzoS et al.

    Hydroxyurea in the treatment of patients with essential thrombocythemia to high risk of thrombosis: a prospective randomized trial

    New England Journal of Medicine

    (1995)
  • DicksteinJI et al.

    Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes

    American Journal of Clinical Pathology

    (1993)
  • DicksteinJI et al.

    Hematopathologic findings in the myeloproliferative disorders

  • EllisJT et al.

    Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and secondary hematologic malignancies

  • FrancoV et al.

    Immunohistochemical evaluations of bone marrow lymphoid nodules in chronic myeloproliferative disorders

    Virchows Archiv A

    (1991)
  • FruchtmanSM et al.

    From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera

  • GaltonDAG

    Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia

    Leukemia and Lymphoma

    (1992)
  • GeorgiiA et al.

    Chronic megakaryocytic granulocytic myelosis—CMGM. A subtype of chronic myeloid leukemia

    Virchows Archive A

    (1980)
  • GeorgiiA et al.

    Hannover classification of chronic myeloproliferative diseases by histopathology of the bone marrow

  • GeorgiiA et al.

    Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies

    Leukemia and Lymphoma

    (1996)
  • GeorgiiA et al.

    Histological classification and grading of bone marrow biopsies provides prognostic data at diagnosis in patients with chronic myeloproliferation

    Hematologica

    (1998)
  • GugliottaL et al.

    Evaluation of thrombopoiesis in essential thrombocythaemia before and after α-interferon treatment

    Thrombosis and Haemostasis

    (1987)
  • HansenFA et al.

    Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

    New England Journal of Medicine

    (1998)
  • HehlmannR

    Editorial: A change of cure for every patient with chronic myeloid leukemia

    New England Journal of Medicine

    (1998)
  • KaloutsiV et al.

    Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities

    Virchows Archive A

    (1991)
  • KantarjianHM et al.

    Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia

    Cancer

    (1986)
  • Cited by (92)

    • Myeloproliferative neoplasms

      2019, Rodak’s Hematology: Clinical Principles and Applications
    • Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?

      2017, Clinical Lymphoma, Myeloma and Leukemia
      Citation Excerpt :

      Thus, the baseline phase remains the most important prognostic factor determining patient outcome. If untreated, CML-CP will progress to the CML-AP or CML-BP within the next 1 to 2 years.10 This risk has become rare, but has not been completely avoided using current TKI therapy; ≤ 20% to 40% of CML-CP cases will eventually develop imatinib resistance or intolerance and require a change of therapy.11

    • Chronic myelogenous leukemia

      2011, Blood and Bone Marrow Pathology: Expert Consult
    • Essential thrombocythemia and primary myelofibrosis

      2011, Blood and Bone Marrow Pathology: Expert Consult
    View all citing articles on Scopus
    View full text